IO Biotech Stock (NASDAQ:IOBT)

Forecast Ownership Financials Chart

Previous Close

$2.06

52W Range

$0.66 - $2.48

50D Avg

$1.49

200D Avg

$1.10

Market Cap

$158.11M

Avg Vol (3M)

$279.44K

Beta

0.36

Div Yield

IOBT Company Profile

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Nov 05, 2021

Website

IOBT Performance

IOBT Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-95.18M	$-91.44M	$-71.42M
Net Income	$-95.49M	$-86.08M	$-71.46M
EBITDA	$-95.18M	$-91.23M	$-69.34M
Basic EPS	$-1.45	$-1.98	$-2.48
Diluted EPS	$-1.45	$-1.98	$-2.48

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
MOLN	Molecular Partners AG
CLYM	Climb Bio, Inc.
HOWL	Werewolf Therapeutics, Inc.
XLO	Xilio Therapeutics, Inc.
EWTX	Edgewise Therapeutics, Inc.
CNTA	Centessa Pharmaceuticals plc
GLTO	Galecto, Inc.